These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 31136750)

  • 1. Colorectal cancer: A paradigmatic model for cancer immunology and immunotherapy.
    IJsselsteijn ME; Sanz-Pamplona R; Hermitte F; de Miranda NFCC
    Mol Aspects Med; 2019 Oct; 69():123-129. PubMed ID: 31136750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy.
    Bai Z; Zhou Y; Ye Z; Xiong J; Lan H; Wang F
    Front Immunol; 2021; 12():808964. PubMed ID: 35095898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
    Picard E; Verschoor CP; Ma GW; Pawelec G
    Front Immunol; 2020; 11():369. PubMed ID: 32210966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.
    Quiroga D; Lyerly HK; Morse MA
    Curr Treat Options Oncol; 2016 Aug; 17(8):41. PubMed ID: 27315067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4.
    van den Bulk J; Verdegaal EME; Ruano D; Ijsselsteijn ME; Visser M; van der Breggen R; Duhen T; van der Ploeg M; de Vries NL; Oosting J; Peeters KCMJ; Weinberg AD; Farina-Sarasqueta A; van der Burg SH; de Miranda NFCC
    Genome Med; 2019 Dec; 11(1):87. PubMed ID: 31888734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Spatial Organization of Suppressive Myeloid Cells and Effector T Cells in Colorectal Cancer-A Potential Tool for Discovering Prognostic Biomarkers in Clinical Research.
    Zwing N; Failmezger H; Ooi CH; Hibar DP; Cañamero M; Gomes B; Gaire F; Korski K
    Front Immunol; 2020; 11():550250. PubMed ID: 33193316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The colorectal cancer immune microenvironment and approach to immunotherapies.
    Koi M; Carethers JM
    Future Oncol; 2017 Aug; 13(18):1633-1647. PubMed ID: 28829193
    [No Abstract]   [Full Text] [Related]  

  • 8. Genomics and emerging biomarkers for immunotherapy of colorectal cancer.
    Kather JN; Halama N; Jaeger D
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):189-197. PubMed ID: 29501787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer.
    Chen H; Yao J; Bao R; Dong Y; Zhang T; Du Y; Wang G; Ni D; Xun Z; Niu X; Ye Y; Li HB
    Mol Cancer; 2021 Feb; 20(1):29. PubMed ID: 33557837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Going beyond microsatellite instability for immunotherapy in metastatic colorectal cancer: Consensus molecular subtypes and tumor mutational burden].
    Cohen R; Heran M; Pudlarz T; Hilmi M; Tournigand C; André T; Rousseau B
    Bull Cancer; 2019 Feb; 106(2):151-161. PubMed ID: 30638897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenomic pathways associated with cytotoxic lymphocyte infiltration and survival in colorectal cancer.
    Shen Y; Guan Y; Hummel JJ; Shyu CR; Mitchem JB
    BMC Cancer; 2020 Feb; 20(1):124. PubMed ID: 32059711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advancing Immunotherapy in Metastatic Breast Cancer.
    Mansour M; Teo ZL; Luen SJ; Loi S
    Curr Treat Options Oncol; 2017 Jun; 18(6):35. PubMed ID: 28534250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Facts and Hopes in Colorectal Cancer Immunotherapy.
    Foote MB; Argilés G; Rousseau B; Segal NH
    Clin Cancer Res; 2023 Oct; 29(20):4032-4039. PubMed ID: 37326624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era.
    Linette GP; Carreno BM
    Curr Hematol Malig Rep; 2019 Aug; 14(4):286-291. PubMed ID: 31187421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges.
    Duan J; Wang Y; Jiao S
    Cancer Med; 2018 Sep; 7(9):4517-4529. PubMed ID: 30088347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer.
    Hirano H; Takashima A; Hamaguchi T; Shida D; Kanemitsu Y;
    Jpn J Clin Oncol; 2021 Jan; 51(1):10-19. PubMed ID: 33205813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
    Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
    Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy Progress in Mismatch Repair-Deficient Colorectal Cancer and Future Therapeutic Challenges.
    Link JT; Overman MJ
    Cancer J; 2016; 22(3):190-5. PubMed ID: 27341597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency.
    Bourdais R; Rousseau B; Pujals A; Boussion H; Joly C; Guillemin A; Baumgaertner I; Neuzillet C; Tournigand C
    Crit Rev Oncol Hematol; 2017 May; 113():242-248. PubMed ID: 28427513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colorectal Cancer Immune Infiltrates: Significance in Patient Prognosis and Immunotherapeutic Efficacy.
    Guo L; Wang C; Qiu X; Pu X; Chang P
    Front Immunol; 2020; 11():1052. PubMed ID: 32547556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.